[1]WHO consulation organized in collaboration with the viral hepatitisprevention board.Global surveillance and control of hepatitis C[J].J Viral Hepat, 1999, 6∶35-47.
|
[2]Manns MP, McHutchison JG, Gordon SC, et al.Peg-interferon al-fa-2b plus ribavirin compared to interferon alfa-2b plus ribavirinfor the treatment of chronic hepatitis C.A randomized trial[J].Lan-cet, 2001, 358 (9286) ∶958-965.
|
[3]Fried MW, Shiffman ML, Reddy KR, et al.Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C infection[J].NEngl J Med, 2002, 347 (13) ∶975-982.
|
[4] 中华医学会.丙型肝炎防治指南[J].中华内科杂志, 2004, 43∶551-555.
|
[5]Shiratori Y, Imazeki F, Moriyama M, et al.Histological improve-ment of fibrosis in patient with hepatitis C who have sustained re-sponse to interferon therapy[J].Ann Intern Med, 2000, 132∶517-524.
|
[6]Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy re-duces the risk for hepatocellular carcinoma development:nature sur-veillance program of cirrhotic and noncirrhotic patients with chronichepatitis C in Japan[J].Ann Intern Med, 1999, 131∶174-181.
|
[7]Imai Y, Kasahara A, Tanaka H, et al.Interferon therapy for agedpatients with chronic hepatitis C:improved survival in patients exhib-iting a biochemical response[J].J Gastroenterol, 2004, 39∶1069-1077.
|
[8]Yoshida H, Arakawa Y, Sata M, et al.Interferon therapy prolongedlife expectancy among chronic hepatitis C patients[J].Gastroenterol-ogy, 2002, 123∶483-491.
|
[9]McHutchison JG, Gordon SC, Schiff ER, et al.Interferon alfa-2balone or in combination with ribavirin as initial treatment for chronichepatitis C.Hepatitis Interventional Therapy Group[J].N Engl JMed, 1998, 339∶1485-1492.
|
[10]Sulkowski MS, Wasserman R, Brooks L, et al.Changes in haemo-globin during interferon alpha-2b plus ribavirin combination therapyfor chronic hepatitis C virus infection[J].J Viral Hepat, 2004, 11∶243-250.
|